FDA-cleared profile

SIGNA Hero

GE Healthcare (GE Medical Systems, LLC) · MRI · FDA-cleared (510(k))

Authorized purpose: SIGNA Hero is a 3.0T whole-body MR system for qualified technologists and interpreting physicians to acquire, reconstruct, display, and export labeled diagnostic MR examinations using supported coils, sequences, and applications.

Clinical role
MRI acquisition, reconstruction, review, and release-specific workflow support.
Images and patients
MRI · Multi-region
Key limitation
Keep in mind: Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: SIGNA Hero is a 3.0T whole-body MR system for qualified technologists and interpreting physicians to acquire, reconstruct, display, and export labeled diagnostic MR examinations using supported coils, sequences, and applications.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Multi-region Input: Patient MRI signal data acquired with supported coils, pulse sequences, field strengths, and release-specific protocols.
  • Who uses it?Intended users: Qualified MRI technologists and physicians trained in magnetic resonance imaging.
  • What does the software produce?Output: Cross-sectional MR images, spectra, derived measurements, and reconstructed series for professional review.
  • What is its most important limitation?Key limitation: Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.

Clinical takeaway. Clinical role: SIGNA Hero is a 3.0T whole-body MR system for qualified technologists and interpreting physicians to acquire, reconstruct, display, and export labeled diagnostic MR examinations using supported coils, sequences, and applications.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports testing to voluntary standards, compliance with applicable NEMA MS standards and the NEMA DICOM standard, biocompatibility testing, and quality assurance measures applied as for the predicate. It states the performance data include bench and clinical testing of image quality compared to the predicate, that clinical studies were not required, and that sample clinical images demonstrate acceptable diagnostic image performance. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
SIGNA Hero is a 3.0T whole-body MR system for qualified technologists and interpreting physicians to acquire, reconstruct, display, and export labeled diagnostic MR examinations using supported coils, sequences, and applications.
  • Exact FDA submission
  • Checked 2026-09-03
Workflow role
MRI acquisition, reconstruction, review, and release-specific workflow support.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Patient MRI signal data acquired with supported coils, pulse sequences, field strengths, and release-specific protocols.
  • Exact FDA submission
  • Checked 2026-09-03
Output and clinician action
Cross-sectional MR images, spectra, derived measurements, and reconstructed series for professional review.
  • Exact FDA submission
  • Checked 2026-09-03
Care setting
Hospital and outpatient MRI departments operating the cleared field strength, coils, protocols, and accessories.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Qualified MRI technologists and physicians trained in magnetic resonance imaging.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.
  • Exact FDA submission
  • Checked 2026-09-03
Evidence summary
The exact FDA document reports testing to voluntary standards, compliance with applicable NEMA MS standards and the NEMA DICOM standard, biocompatibility testing, and quality assurance measures applied as for the predicate. It states the performance data include bench and clinical testing of image quality compared to the predicate, that clinical studies were not required, and that sample clinical images demonstrate acceptable diagnostic image performance. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Testing to the following voluntary standards included:" … "In addition, the SIGNA™ Hero complies with applicable NEMA MS 3, NEMA MS 4, NEMA MS 8, and the NEMA PS3 standard for DICOM, as does the predicate device.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports testing to voluntary standards, compliance with applicable NEMA MS standards and the NEMA DICOM standard, biocompatibility testing, and quality assurance measures applied as for the predicate. It states the performance data include bench and clinical testing of image quality compared to the predicate, that clinical studies were not required, and that sample clinical images demonstrate acceptable diagnostic image performance. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Testing to the following voluntary standards included:" … "In addition, the SIGNA™ Hero complies with applicable NEMA MS 3, NEMA MS 4, NEMA MS 8, and the NEMA PS3 standard for DICOM, as does the predicate device.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K213668 FDA performance package for SIGNA Hero

  • DesignManufacturer MR hardware, software, image-quality, sample-clinical-image, safety, EMC, and usability verification and validation submitted in K213668
  • PopulationWhole-body diagnostic MR examinations across the cleared field strength, coils, sequences, anatomies, and supported patient workflows
  • Scopeexact submission
  • Tested versionSIGNA Hero (K213668)
  • IndependenceSponsor or vendor study

K213668

Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
2 exact-submission FDA recall records in the 2026-09-02 openFDA snapshot identify K213668. Affected model, version, unit, correction, and current manufacturer instructions still require local confirmation. FDA recall Z-2308-2025 is Open, Classified for GE SIGNA Hero, Nuclear Magnetic Resonance Imaging System. FDA reason: GE HealthCare has become aware that for certain MR systems (SIGNA Artist, SIGNA Voyager, Discovery MR450 1.5T, Optima MR450w 1.5T, SIGNA Architect, SIGNA Premier, SIGNA UHP, Discovery MR750 3.0T, Discovery MR750w 3.0T, SIGNA Hero, SIGNA PET/MR, SIGNA Artist Evo, SIGNA Voyager AIR (China Only), SIGNA Architect AIR (China Only), SIGNA Premier XT (China Only), SIGNA Premier Elite (China Only), SIGNA Premier MAX (China Only), SIGNA Hero XT (China Only), SIGNA Hero Elite (China Only), SIGNA Hero MAX (China Only), SIGNA PET/MR AIR (China Only), SIGNA PET/MR AIR Plus (China Only), the planned maintenance steps to check the functionality of the caster locks on the MR patient table may not have been performed. FDA action: GE HealthCare issued an URGENT CORRECTION NOTICE to it consignees on 06/20/2025 via traceable means. The notice explained the safety issue and requested the following actions be taken: "You can continue to use your MR system by following the instructions below: In the undocked position, lock the table by pressing the pedal in the front of the table. Check to see that all casters are locked and that the table is secure. Contact your GE HealthCare representative for assistance if any of the casters do not lock. Before each patient transfer verify that the caster locks are engaged. If you notice more than one caster is damaged or fails to lock properly, use particular caution as the table may move while in use. No additional steps are required to continue to use your table in the docked position. Please ensure all potential users in your facility are made aware of this safety notification and the recommended actions." "GE HealthCare will inspect and if necessary, correct all affected products at no cost to you. A GE HealthCare representative will contact you to arrange for the correction." " if you have any questions for concerns regarding this notification, please contact GE HealthCare Service at 1-800-437-1171 or your local Service Representative." FDA recall Z-2461-2024 is Open, Classified for SIGNA Hero, with affected software versions: PX29.1, MR30.0, MR30.1; Nuclear Magnetic Resonance Imaging System. FDA reason: GE HealthCare has become aware that for certain MR systems, the system predicted B1+RMS value can exceed the B1+RMS user prescribed limit when scanning in Low SAR Mode and the following two conditions are met: 1. 2D FSE T2 FLAIR OR T2 FLAIR Propeller imaging sequence is selected, AND 2. the Optimized T2 FLAIR sequence option is turned off OR not included in the MR configuration. If this occurs, it can result in overheating of an MR conditional implant. FDA action: GE Healthcare issue an URGENT MEDICAL DEVICE CORRECTION to its consignees via letter on 06/14/2024. The letter explained the problem with the device, safety issue, and requested the following: "Actions to be taken by Customer/User: You can continue to use your MR system by following the instructions below: To ensure that the displayed B1+RMS value on the Scan Prescription User Interface does not exceed the user prescribed limit specified in the Low SAR Mode User Interface: " If your software version includes the Optimized T2 FLAIR Sequence option, enable this option by setting the value to 1.00. This option is present on the Advanced Tab of the Scan Prescription User Interface. " If your software version does not include the Optimized T2 FLAIR Sequence option, adjust scan parameters such as TR , # Slices or Auto Refocus Flip Angle until the displayed B1+RMS value on the Scan Prescription User Interface does not exceed the user prescribed limit. Please ensure all potential users in your facility are made aware of this safety notification and the recommended actions." GE HealthCare will correct all affected products at no cost to you. A GE HealthCare representative will contact you to arrange for the correction. If you have any questions or concerns regarding this notification, please contact GE HealthCare Service at 1-800-437-1171 or your local Service Representative.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-2308-2025

Open, Classified

2025-08-13

Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; the FDA record does not identify an AI-algorithm defect unless it says so. Confirm affected model, version, units, corrective action, and completion status locally.

recall: Z-2461-2024

Open, Classified

2024-08-02

Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; the FDA record does not identify an AI-algorithm defect unless it says so. Confirm affected model, version, units, corrective action, and completion status locally.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Patient MRI signal data acquired with supported coils, pulse sequences, field strengths, and release-specific protocols.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-03 · FDA 510(k) decision summary K213668: SIGNA Hero

  2. Routing

    Source context, not route validation: Scanner-console and DICOM workflow to PACS or downstream applications; validate worklist, identifiers, series labels, geometry, measurements, routing, and archive completeness.

    Scope: Product family. Current vendor materials are product-family evidence for K213668; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA 510(k) decision summary K213668: SIGNA Hero · GE SIGNA Hero 3T MRI

  3. AI processing

    Source context, not route validation: Installed MRI hardware and release-specific scanner software with licensed coils, sequences, reconstruction options, and accessories.

    Scope: Product family. Current vendor materials are product-family evidence for K213668; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA 510(k) decision summary K213668: SIGNA Hero · GE SIGNA Hero 3T MRI

  4. Returned objects

    Source context, not route validation: Cross-sectional MR images, spectra, derived measurements, and reconstructed series for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-03 · FDA 510(k) decision summary K213668: SIGNA Hero

  5. Viewer/worklist/report

    Unresolved route: Cross-sectional MR images, spectra, derived measurements, and reconstructed series for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-03 · FDA 510(k) decision summary K213668: SIGNA Hero

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Installed MRI hardware and release-specific scanner software with licensed coils, sequences, reconstruction options, and accessories.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K213668; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Integration
Scanner-console and DICOM workflow to PACS or downstream applications; validate worklist, identifiers, series labels, geometry, measurements, routing, and archive completeness.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K213668; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Security
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: GE HealthCare's own Privacy Shield page on gehealthcare.com names GE Medical Systems LLC as a US entity of the GEHC group. Corporate program statement; portal content is credentialed; exact-release scope is not established.

Training
Only qualified mri technologists and physicians trained in magnetic resonance imaging should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K213668; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled AI functions to K213668 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Scanner-console and DICOM workflow to PACS or downstream applications; validate worklist, identifiers, series labels, geometry, measurements, routing, and archive completeness.

product family · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.

product family · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K213668
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-01-20
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 2 FDA recall candidates were manually reviewed: 2 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 2 postmarket candidate records; 2 have been reviewed (2 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

10 sources - 3 history items

Source ledger

  1. FDA 510(k) decision summary K213668: SIGNA Hero

    U.S. Food and Drug Administration - Published 2026-09-03 - Accessed 2026-09-03

    Scope: purpose, modality, anatomy, intendedUsers, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. FDA recall Z-2308-2025: GE SIGNA Hero, Nuclear Magnetic Resonance Imaging System

    U.S. Food and Drug Administration - Published 2025-08-13 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  4. FDA recall Z-2461-2024: SIGNA Hero, with affected software versions: PX29.1, MR30.0, MR30.1; Nuclear Magnetic Resonance Imaging System

    U.S. Food and Drug Administration - Published 2024-08-02 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  5. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  6. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  7. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  8. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  9. GE SIGNA Hero 3T MRI

    GE HealthCare - Accessed 2026-09-03

    Scope: productFamilyContext, workflowRole, implementationCapabilities

  10. GE HealthCare: Product Security (portal and Cybersecurity Risk Management System)

    GE HealthCare - Accessed 2026-10-26

    Scope: security

Research history

  1. K213668 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260746

S-scan Open (100001800)

Esaote, S.p.A.

Authorized purpose: S-scan Open is an Esaote MR system for diagnostic image acquisition, reconstruction, display, and professional interpretation within the labeled scanner, coil, sequence, and anatomy scope.

Modality
MRI
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K252379

AIR Recon DL

Ge Medical Systems, LLC

Authorized purpose: AIR Recon DL adds a deep-learning phase-correction and reconstruction option to supported GE 1.5T, 3T, and 7T MR workflows for all labeled anatomies and ages to reduce noise or ringing and support image quality or scan-time choices.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K252838

MAGNETOM Sola; MAGNETOM Altea; MAGNETOM Sola Fit; MAGNETOM Viato.Mobile; MAGNETOM Vida; MAGNETOM Lumina; MAGNETOM Vida Fit; MAGNETOM Flow.Elite; MAGNETOM Flow.Neo; MAGNETOM Flow.Rise

Siemens Healthcare GmbH

Authorized purpose: The listed MAGNETOM 1.5T and 3T MRI systems produce cross-sectional images, spectroscopic images or spectra, and derived physical parameters of the head, body, and extremities for trained-physician interpretation and can support imaging during MR-compatible interventions.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history